Planned Treatment Interruptions and Chemotherapy-Free Intervals in the Treatment of Metastatic Colorectal Cancer: Time to Start Stopping?

References 

1. Green E, Sargent DJ, Goldberg RM, et al: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Presented at 2005 ASCO Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to Gastrointestinal Malignancies and Premalignancies, January 27–29, 2005, Hollywood, FL. (abstr 182). Available at: http://www.asco.org
2. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: A GERCOR study. J Clin Oncol. 2006;24:394–400
   • CrossRef
3. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol. 2006;24(suppl):3504A;(abstr)
4. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous FOLFIRI in advanced colorectal cancer (ACC): A randomized GISCAD trial. J Clin Oncol. 2006;24(suppl):3505A;(abstr)
5. Tournigand C, Perez N, Buyse M, et al. OPTIMOX study: Influence of reintroduction rate on survival. Ann Oncol. 2004;15(suppl 3):344P;(abstr)
6. Lal R, Dickson J, Cunningham D, et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol. 2004;22:3023–3031
   • MEDLINE
   • CrossRef
7. Chen HX, Mooney M, Boron M, et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). J Clin Oncol. 2006;22(suppl):3515A;(abstr)
8. Giantonio BJ, Catalano PI, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;23(suppl):2A;(abstr)